50
Participants
Start Date
April 16, 2024
Primary Completion Date
April 30, 2027
Study Completion Date
April 30, 2027
Endocrinologist-directed target blood glucose level 4-10 mmol/L using data from a continuous glucose monitor (CGM)
Standard anti-hyperglycemic treatment given as directed by an endocrinologist to maintain blood glucose level within 4-10 mmol/L based on data from a continuous glucose monitor (CGM) and standard blood work drawn prior to each cycle of chemotherapy. Participants will have access to their glucose data from the CGM.
Standard Care
Standard anti-hyperglycemic treatment given only if blood glucose level is greater than 15 mmol/L as measured from standard blood work drawn prior to each cycle of chemotherapy. Participants will wear a continuous glucose monitor (CGM) but will not have access to their glucose data. Participants may be referred to an endocrinologist at the discretion of their medical oncologist.
RECRUITING
British Columbia Cancer, Vancouver
RECRUITING
Princess Margaret Cancer Centre, Toronto
University of British Columbia
OTHER
Lustgarten Foundation
OTHER
University Health Network, Toronto
OTHER
British Columbia Cancer Agency
OTHER